Skip to main content
SpringerLink
Log in

HBV Therapy and the Problem of Drug Resistance

  • Reference work entry
  • First Online:
Handbook of Antimicrobial Resistance

Abstract

The current goal of management for patients with chronic hepatitis B is to achieve sustained virological suppression. This has been shown to reduce the risk of liver disease progression, including cirrhosis, hepatic failure, and hepatocellular carcinoma. Nucleos(t)ide analogue monotherapy is commonly used as first-line therapy, and most patients will require long-term antiviral therapy. As for all direct-acting antiviral agents, the emergence of drug resistance is an important clinical concern. In this chapter, we discuss the principles of HBV antiviral resistance and clinical pathways for preventing the selection of drug-resistant variants, as well as appropriate management strategies for antiviral treatment failure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 449.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 699.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Angus P et al (2003) Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125(2):292–297

    Article  PubMed  Google Scholar 

  • Bartholomeusz A et al (2005) Mechanistic basis for HBV resistance to acyclic nucleoside phosphonate analogues, adefovir and tenofovir. Hepatology 42:594A

    Google Scholar 

  • Bartholomew MM et al (1997) Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349(9044):20–22

    Article  CAS  PubMed  Google Scholar 

  • Berg T et al (2010) Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 139(4):1207–1217

    Article  CAS  PubMed  Google Scholar 

  • Berg T et al. (2014) Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 60(4):715–22

    Google Scholar 

  • Brunelle MN et al (2005) Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41(6):1391–1398

    Article  CAS  PubMed  Google Scholar 

  • Chan HL et al (2013) Tenofovir df (tdf) compared to emtricitabine (ftc)/tdf in hbeag-positive, chronic hepatitis b (chb) virusinfected patients in the immune tolerant (it) phase. J Hepatol Vol 52 (Suppl 1): S45 (A101)

    Google Scholar 

  • Chang TT, Lai CL (2006) Hepatitis B virus with primary resistance to adefovir. N Engl J Med 355:322–323; author reply 323

    Article  CAS  PubMed  Google Scholar 

  • Chang TT et al (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52(3):886–893

    Article  CAS  PubMed  Google Scholar 

  • Chen CJ et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65–73

    Article  CAS  PubMed  Google Scholar 

  • Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350(10):1023–1035

    Article  CAS  PubMed  Google Scholar 

  • Clements CJ et al (2010) Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull World Health Organ 88(1):66–73

    Article  PubMed  Google Scholar 

  • Colonno RJ et al (2006) Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44(6):1656–1665

    Article  CAS  PubMed  Google Scholar 

  • Delaney WE et al (2003) The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77(21):11833–11841

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Domingo E (2003) Quasispecies and the development of new antiviral strategies. Prog Drug Res 60:133–158

    CAS  PubMed  Google Scholar 

  • European Association for the Study of the Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57(1):167–185

    Article  Google Scholar 

  • Fung SK et al (2005) Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 43(6):937–943

    Article  CAS  PubMed  Google Scholar 

  • Fung SK et al (2006) Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44(2):283–290

    Article  CAS  PubMed  Google Scholar 

  • Gish R et al (2012) Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 12(4):341–353

    Article  PubMed  Google Scholar 

  • Hadziyannis SJ et al (2006) Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131(6):1743–1751

    Article  CAS  PubMed  Google Scholar 

  • Harrison TJ (2006) Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis 26(2):87–96

    Article  CAS  PubMed  Google Scholar 

  • Iloeje UH et al (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130(3):678–686

    Article  PubMed  Google Scholar 

  • Kamili S et al (2009) Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 49(5):1483–1491

    Article  CAS  PubMed  Google Scholar 

  • Keeffe EB et al (2007) Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5(8):890–897

    Article  PubMed  Google Scholar 

  • Lai MW, Yeh CT (2008) The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther 13(7):875–879

    CAS  PubMed  Google Scholar 

  • Lai CL et al (2003) Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36(6):687–696

    Article  CAS  PubMed  Google Scholar 

  • Lai CL et al (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357(25):2576–2588

    Article  CAS  PubMed  Google Scholar 

  • Lai MW et al (2009) Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther 14(2):249–261

    CAS  PubMed  Google Scholar 

  • Lavocat F et al (2013) Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol 59(4):684–695

    Article  CAS  PubMed  Google Scholar 

  • Lee YS et al (2006) Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43(6):1385–1391

    Article  CAS  PubMed  Google Scholar 

  • Liaw YF et al (2004a) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15):1521–1531

    Article  CAS  PubMed  Google Scholar 

  • Liaw YF, Chien RN, Yeh CT (2004b) No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 9(2):257–262

    CAS  PubMed  Google Scholar 

  • Liaw Y-F et al (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6:531–561

    Article  PubMed  Google Scholar 

  • Liu Y et al (2010) Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther 15(8):1185–1190

    Article  PubMed  Google Scholar 

  • Locarnini SA (1998) Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 27(1):294–297

    Article  CAS  PubMed  Google Scholar 

  • Locarnini S, Qi X, Arterturn S (2005) Incidence and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil therapy for patients with chronic hepatitis B. J Hepatol 42(Suppl 1):754A

    Google Scholar 

  • Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50(3):661–662

    Article  PubMed  Google Scholar 

  • Lok AS et al (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125(6):1714–1722

    Article  CAS  PubMed  Google Scholar 

  • Lok AS et al (2007) Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46(1):254–265

    Article  CAS  PubMed  Google Scholar 

  • Lok AS et al (2012) Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 143(3):619–628.e1

    Article  CAS  PubMed  Google Scholar 

  • Lozano R et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095–2128

    Article  PubMed  Google Scholar 

  • Nafa S et al (2000) Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32(5):1078–1088

    Article  CAS  PubMed  Google Scholar 

  • Ogata N et al (1999) Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 59(3):270–276

    Article  CAS  PubMed  Google Scholar 

  • Ogura Y et al (1999) Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. J Infect Dis 180(5):1444–1451

    Article  CAS  PubMed  Google Scholar 

  • Patterson SJ et al (2011) Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60(2):247–254

    Article  CAS  PubMed  Google Scholar 

  • Pol S, Sogni P (2010) Treatment of chronic hepatitis B: adherence and safety. Gastroenterol Clin Biol 34(Suppl 2):S142–S148

    Article  PubMed  Google Scholar 

  • Schluter V et al (1994) Integrated hepatitis B virus X and 3′ truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene 9(11):3335–3344

    CAS  PubMed  Google Scholar 

  • Shaw T, Locarnini S (2004) Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2(6):853–871

    Article  CAS  PubMed  Google Scholar 

  • Shields PL et al (1999) Selection of hepatitis B surface “escape” mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Gut 45(2):306–309

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sloan RD et al (2008) Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 13(3):439–447

    PubMed  Google Scholar 

  • Snow-Lampart A et al (2011) No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53(3):763–773

    Article  CAS  PubMed  Google Scholar 

  • Tenney DJ et al (2004) Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48(9):3498–3507

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tenney DJ et al (2009) Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49(5):1503–1514

    Article  CAS  PubMed  Google Scholar 

  • Thibault V et al (2002) Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 16(1):131–133

    Article  PubMed  Google Scholar 

  • Tipples GA et al (1996) Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24(3):714–717

    CAS  PubMed  Google Scholar 

  • Torresi J et al (2002a) Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293(2):305–313

    Article  CAS  PubMed  Google Scholar 

  • Torresi J et al (2002b) Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “fingers” subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299(1):88–99

    Article  CAS  PubMed  Google Scholar 

  • van Bommel F et al (2010) Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51(1):73–80

    Article  PubMed  Google Scholar 

  • Villeneuve JP et al (2003) Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39(6):1085–1089

    Article  CAS  PubMed  Google Scholar 

  • Villet S et al (2006) Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131(4):1253–1261

    Article  PubMed  Google Scholar 

  • Villet S et al (2007) Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 46(3):531–538

    Article  CAS  PubMed  Google Scholar 

  • Villet S et al (2008) Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 48(5):747–755

    Article  CAS  PubMed  Google Scholar 

  • Warner N, Locarnini S (2008) The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48(1):88–98

    Article  CAS  PubMed  Google Scholar 

  • Yeon JE et al (2006) Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55(10):1488–1495

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yim HJ et al (2006) Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44(3):703–712

    Article  CAS  PubMed  Google Scholar 

  • Yuen MF et al (2001) Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34(4 Pt 1):785–791

    Article  CAS  PubMed  Google Scholar 

  • Yuen LK et al (2007) SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 75(1):64–74

    Article  CAS  PubMed  Google Scholar 

  • Zhou T et al (1999) Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 43(8):1947–1954

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zollner B et al (2001) Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 65(4):659–663

    Article  CAS  PubMed  Google Scholar 

  • Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(5):1593–1608.e1-2

    Article  CAS  PubMed  Google Scholar 

  • Zoulim F, Locarnini S (2012) Management of treatment failure in chronic hepatitis B. J Hepatol 56(Suppl 1):S112–S122

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, St Vincent’s Hospital Melbourne and The University of Melbourne, Fitzroy, VIC, Australia

    A. J. Thompson

  2. Victorian Infectious Diseases Reference Laboratory, North Melbourne, VIC, Australia

    A. J. Thompson & S. A. Locarnini

Authors
  1. A. J. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. A. Locarnini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. J. Thompson .

Editor information

Editors and Affiliations

  1. Department of Microbiology and Immunology, McGill University, Montreal, Québec, Canada

    Albert Berghuis

  2. Department of Microbiology and Immunology, McGill University, Montreal, Québec, Canada

    Greg Matlashewski

  3. Department of Microbiology and Immunology, McGill University, Montreal, Québec, Canada

    Mark A. Wainberg

  4. Department of Microbiology and Immunology, McGill University, Montreal, Québec, Canada

    Donald Sheppard

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this entry

Cite this entry

Thompson, A.J., Locarnini, S.A. (2017). HBV Therapy and the Problem of Drug Resistance. In: Berghuis, A., Matlashewski, G., Wainberg, M., Sheppard, D. (eds) Handbook of Antimicrobial Resistance. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0694-9_4

Download citation

Publish with us

Policies and ethics

Search

Navigation